Pharmacological dose ascorbic acid administration in relapsed refractory multiple myeloma patients

Sonneveld, 2016, Treatment of relapsed and refractory multiple myeloma, Haematologica, 101, 396, 10.3324/haematol.2015.129189 Cameron, 1974, The orthomolecular treatment of cancer. II. Clinical trial of high-dose ascorbic acid supplements in advanced human cancer, Chem. Biol. Interact., 9, 285, 10.1016/0009-2797(74)90019-2 Kaiser, 2013, Global methylation analysis identifies prognostically important epigenetically inactivated tumour suppressor genes in multiple myeloma, Blood, 122, 219, 10.1182/blood-2013-03-487884 Yin, 2013, Ascorbic acid enhances Tet-mediated 5-methylcytosine oxidation and promotes DNA demethylation in mammals, J. Am. Chem. Soc., 135, 10396, 10.1021/ja4028346 Mehdi, 2013, Investigation of the antioxidant status in multiple myeloma patients: effects of therapy, Asian Pac J Cancer Prev, 14, 3663, 10.7314/APJCP.2013.14.6.3663 Ixa, 2017, Multiple myeloma tumor cells are selective killed by pharmacologically-dose ascorbic acide, EBioMedicine, 8, 41 Stewart, 2015, Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma, N. Engl. J. Med., 372, 142, 10.1056/NEJMoa1411321 Smirnova, 2014, The relationship between thepro-oxidant and antioxidant system status of patients with multiple myeloma and the disease stage, Bull. Exp. Biol. Med., 157, 375, 10.1007/s10517-014-2570-5 Sharma, 2009, Study of a patients with multiple myeloma, Leuk Lymphoma, 50, 809, 10.1080/10428190902802323 Campbell, 2004, Ascorbic acid overcomes drug resistance in myeloma and significantly increases the anti-myeloma effects of both arsenic trioxide and melphalan in vitro and in vivo, Blood, 104, 247 Yun, 2015, Vitamin C selectively kills KRAS and BRAF mutant colorectal cancer cells by targeting GAPDH, Science, 350, 1391, 10.1126/science.aaa5004 Nishikawa, 2008, Reactive oxygen species in tumor metastasis, Cancer Lett., 266, 53, 10.1016/j.canlet.2008.02.031 Bahlis, 2002, Feasibility and correlates of arsenic trioxide combined with ascorbic acid-mediated depletion of intracellular glutathione for the treatment of relapsed/refractory multiple myeloma, Clin. Cancer Res., 8, 3658 Perrone, 2009, Ascorbic acid inhibits antitumor activity of bortezomib in vivo, Leukemia, 23, 1679, 10.1038/leu.2009.83 Berenson, 2009, Bortezomib, ascorbic acid and melphalan (BAM) therapy for patients with newly diagnosed multiple myeloma: an effective and well-tolerated frontline regimen, Eur. J. Haematol., 82, 433, 10.1111/j.1600-0609.2009.01244.x Li, 2015, The clinical activity of arsenic trioxide, ascorbic acid, ifosfamide and prednisone combination therapy in patients with relapsed and refractory multiple myeloma, Onco Targets Ther., 8, 775, 10.2147/OTT.S81022 Held, 2013, A phase I study of arsenic trioxide (Trisenox), ascorbic acid, and bortezomib (velcade) combination therapy in patients with relapsed/refractory multiple myeloma, Cancer Invest., 31, 172, 10.3109/07357907.2012.756109 Wu, 2006, Phase II multicenter study of arsenic trioxide, ascorbic acid and dexamethasone in patients with relapsed or refractory multiple myeloma, Haematological, 91, 1722 Qian, 2020, Efficiency and tolerability of induction and consolidation therapy with arsenic trioxide/bortezomib/ascorbic acid/dexamethasone (ABCD) regimen compared to bortezomib/dexamethasone (bd) regimen in newly diagnosed myeloma patient, Cancer Manag Res, 12, 432, 10.2147/CMAR.S212455 Welsh, 2009, Pharmacological ascorbate with gemcitabine for the control of metastatic and node-positive pancreatic cancer (PACMAN): results from a phase I clinical trial, Cancer Chemother. Pharmacol., 7, 765 Mikirova, 2013, Clinical experience with intravenous administration of ascorbic acid: achievable levels in blood for different states of inflammation and disease in cancer patients, J. Transl. Med., 11, 191, 10.1186/1479-5876-11-191 Chen, 2008, Pharmacologic doses of ascorbate act as a prooxidant and decrease growth of aggressive tumor xenografts in mice, Proc. Natl. Acad. Sci. USA, 105, 11105, 10.1073/pnas.0804226105 Klimant, 2018, Intravenous vitamin C in the supportive care of cancer patients: a review and rational approach, Curr Oncol, 25, 10.3747/co.25.3790 Violet, 2017, Pharmacologic ascorbate in myeloma treatment: doses matter, EBioMedicine, 18, 9, 10.1016/j.ebiom.2017.03.014